Radiotherapy for high grade clinically localized adenocarcinoma of the prostate

Journal of Urology

Volumn 156, Issue 5, 1996, Pages 1719-1723

  Roach III, Mack ^a   Meehan, Shane ^b   Kroll, Stewart ^b   Weil, Michael ^b   Ryu, Janice ^b   Small, Eric J ^b   Margolis, Lawrence W ^b   Presti, Joseph ^b   Carroll, Peter C ^b   Phillips, Theodore L ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

adenocarcinoma; prostatic neoplasms; radiotherapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RADIOTHERAPY; CLINICAL ARTICLE; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RADIATION DOSE; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

EID: 10244225226     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)65490-9     Document Type: Article

References (18)

1. Boring, C. C., Squires, T. S. and Tong, T.: Cancer statistics 1993. CA, 43: 7, 1993.
2. Aprikian, A. G., Zhang, Z. F. and Fair, W. R.: Prostate adenocarcinoma in men younger than 50 years. A retrospective review of 151 patients. Cancer, 74: 1768, 1994.
3. Chodak, G. W., Thisted, R. A., Gerber, G. S., Johansson, J.-E., Adolsson, J., Jones, G. W., Chisholm, G. D., Moskovitz, B., Livine, P. M. and Warner, J.: Results of conservative management of clinically localized prostate cancer. New Engl. J. Med., 330: 242, 1994.
4. Partin, A. W., Lee, B. R., Carmichael, M., Walsh, P. C. and Epstein, J. I.: Radical prostatectomy for high grade disease: a reevaluation 1994. J. Urol., 151: 1583, 1994.
5. Ohori, M., Goad, J. R., Wheeler, T. M., Eastham, J. A., Thompson, T. C. and Scardino, P. T.: Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J. Urol., part 2, 152: 1843, 1994.
6. Zagars, G. K., Pollack, A., Kavadi, V. S. and von Eschenbach, A. C.: Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int. J. Rad. Oncol. Biol. Phys., 32: 293, 1995.
7. Zietman, A. L. Coen, J. J., Shipley, W. U., Willett, C. G. and Efird, J. T.: Radical radiation therapy in the management of prostate adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. J. Urol., 151: 650, 1994.
8. Kaplan, E. L. and Meier, P.: Nonparametric estimation from incomplete observations. Amer. Stat. Ass., 53: 457, 1958.
9. Cox, D. R.: Regression models and life tables. J. Roy. Stat. Soc., 34: 187, 1972.
10. Kaplan, I. D., Cox, R. S. and Bagshaw, M. A.: Prostate specific antigen after external beam radiotherapy for prostatic cancer: followup. J. Urol., 149: 519, 1993.
11. Zietman, A. L., Coen, J. J., Dallow, K. C. and Shipley, W. U.: The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome. Int. J. Rad. Oncol. Biol. Phys., 32: 287, 1995.
12. Petrovich, Z., Lieskovsky, G., Freeman, J., Luxton, G., Groshen, S., Formenti, S., Baert, L., Chen, S. and Skinner, D. G.: Sur gery with adjuvant irradiation in patients with pathology stage C adenocarcinoma. Cancer, 76: 1621, 1995.
13. Bagshaw, M. A.: Current conflicts in the management of pro tatic cancer. Int. J. Rad. Oncol. Biol. Phys., 12: 1721, 1986.
14. Hanks, G. E., Lee, W. R., Hanlon, A. L., Kaplan, E., Epstein, and Schultheiss, T. E.: Conformal technique dose escaltion prostate cancer: improved cancer control with higher doses patients with pretreatment PSA ≥10 ngm/ml. Int. J. Rad. Oncol. Biol. Phys., suppl. 1, 32: 141, abstract 2, 1995.
15. Shipley, W. U., Verhey, L. J., Munzenrider, J. E., Suit, H. I Urie, M. M., McManus, P. L., Young, R. H., Shipley, J. V Zietman, A. L., Biggs, P. J., Heney, N. M. and Goitein, M Advanced prostate cancer: the results of a randomized com parative trial of high dose irradiation boosting with conform protons compared with conventional dose irradiation using photons alone. Int. J. Rad. Oncol. Biol. Phys., 32: 3, 1995.
16. Roach, M., III.: Re: the use of prostate specific antigen, clinica stage and Gleason score to predict pathologic stage in me with localized prostate cancer. Letter to the editor. J. Urol 150: 1923, 1993.
17. Zeitman, A. L., Dallow, K. C., Shipley, W. U., Heney, N. M. and McManus, P. L.: Time to second prostate specific antigen (PSA) failure is a surrogate endpoint for prostate cancer death in prospective trials of therapy for localized disease. Int. J Rad. Oncol. Biol. Phys., suppl. 1, 32: 229, abstract 1013, 1995
18. Bermudez, M.-A., Roach, M., Rosenthal, S., Ryu, J., Hunter, D., Holland, J. and Phillips, T. L.: The impact of age and conformal technique on acute toxicity in patients receiving radiation therapy for clinically localized prostate cancer. Int. J. Rad. Oncol. Biol. Phys., suppl. 1, 32: 253, abstract 1061, 1995.